Navigation Links
Estrogen-Only Therapy May Reduce Breast Cancer Risk
Date:3/7/2012

By Denise Mann
HealthDay Reporter

TUESDAY, March 6 (HealthDay News) -- Some women who take estrogen-only hormone replacement therapy to stave off hot flashes, night sweats and other symptoms of menopause may be at lower risk for developing breast cancer down the road, a news study says.

Hormone replacement therapy (HRT) fell from grace rather dramatically after a large government-run trial, the U.S. Women's Health Initiative, was stopped early in 2002 because HRT was shown to increase the risk of strokes and breast and ovarian cancer. Since that time, however, some subtleties have emerged as researchers parsed the evidence further. For example, short-term use of HRT is now deemed fairly safe for some women who have severe menopausal symptoms.

The new study shows that longer-term use of estrogen-only therapy may actually lower a woman's odds of developing breast cancer. Estrogen-only therapy is reserved for women who have had a hysterectomy; women with an intact uterus who use HRT must take the hormone progestin with estrogen to prevent uterine cancer.

"Women who have had a hysterectomy may be reassured that taking estrogen by itself, short term, to relieve menopausal symptoms will not increase their risk of breast cancer," said study author Garnet Anderson of the Women's Health Initiative Clinical Coordinating Center at the Fred Hutchinson Cancer Research Center in Seattle. Women should not take estrogen to prevent breast cancer, she stressed.

The new findings were published in the March 7 online edition of The Lancet Oncology.

The North American Menopause Society recently released a position statement that backs up these findings. The group said starting combination hormone therapy (both estrogen and progestin) around the time of menopause to treat symptoms and stave off the brittle-bone disease osteoporosis is safe for some women for three to five years. Estrogen alone can be used for longer than the combination HRT, according to the society.

The new study, which was partially funded by drug manufacturer Wyeth, included more than 7,500 women from the Women's Health Initiative who took estrogen for about six years. Roughly five years after stopping treatment, the women were 23 percent less likely to develop breast cancer when compared to their counterparts who never used HRT.

Women in the estrogen group who did develop breast cancer were 63 percent less likely to die from the disease, compared to women who never took it. The lower risk of breast cancer was seen only among women without risk factors for breast cancer, such as a history of benign breast disease or a strong family history of breast cancer, the study showed.

"The story is pretty clear about estrogen plus progestin -- no matter the age of the women, estrogen plus progestin increases [the risk of] breast cancer, heart disease, stroke and blood clots," Anderson said. "These risks outweigh the benefits for all age groups."

Why estrogen alone may lower breast cancer risk while adding progestin seems to increase the risk is the million dollar question.

"There are hypotheses about the role of estrogen in breasts after a woman has gone through menopause," Anderson said. For example, "her breast tissue, including any precancerous cells, may go through changes as a result of menopause that make them susceptible to estrogen in a way that discourages cell growth."

Estrogen-only therapy is not without risks, however. For estrogen alone, the Women's Health Initiative data showed no overall effect of estrogen on heart disease, but an increased risk of strokes and blood clots.

Women are understandably confused about whether they should take hormones to treat their menopausal symptoms, and for how long they can safely use the therapy.

"The best use of estrogen-alone is in women with a hysterectomy who need relief of hot flashes and night sweats and related menopausal symptoms," Anderson said. These benefits need to be weighed against a woman's risk of stroke or developing blood clots.

Dr. Lila Nachtigall, a professor of obstetrics and gynecology at NYU Langone Medical Center in New York City, agreed that, when used on its own, estrogen can still be safe and effective in treating the symptoms of menopause in women who do not have a uterus.

"It looks very definite that the bad guy is progestin, not estrogen," Nachtigall said. Her advice is to use the lowest effective dose for the shortest amount of time. If more women took estrogen, she said, there would be a dent made in the epidemic of osteoporosis. "Millions of women who never went on estrogen, even for a few years, are really losing bone," she said.

That said, estrogen does increase the risk of blood clots. "Women with blood-clotting disorders should not take it," Nachtigall said.

Commenting on the study, Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City, said, "If you are looking to reduce menopausal symptoms and don't have an intact uterus, [estrogen] is an option." But estrogen-only therapy should not be prescribed indiscriminately, she added.

"This applies only to women who have severe menopausal symptoms. We are not saying that we should give women estrogen to reduce the risk of breast cancer," Bernik added.

More information

Learn more about the benefits and risks of hormone replacement therapy through the North American Menopause Society.

SOURCES: Lila Nachtigall, M.D., professor, obstetrics and gynecology, NYU Langone Medical Center, New York City; Garnet Anderson, Ph.D., principal investigator, Women's Health Initiative Clinical Coordinating Center, Fred Hutchinson Cancer Research Center, Seattle; Stephanie Bernik, M.D., chief, surgical oncology, Lenox Hill Hospital, New York City; March 7, 2012, The Lancet Oncology, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Estrogen-Only Hormone Therapy May Reduce Breast Cancer Risk for Some
2. Internet-based therapy relieves persistent tinnitus
3. New universal platform for cancer immunotherapy developed by Penn-led team
4. A culprit behind brain tumor resistance to therapy
5. How chemotherapy becomes more effective
6. New approach to stroke therapy
7. Researchers find sarcoma tumor immune response with combination therapy
8. Web-Based Therapy May Help Teens With Chronic Fatigue
9. Combination therapy may enhance gemcitabine activity
10. First study on long-term cognitive effects of breast cancer chemotherapy finds subtle impairment among women who received CMF regimen
11. Aurora-A hinders tumor-suppressor to allow chemotherapy resistance
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Estrogen-Only Therapy May Reduce Breast Cancer Risk
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
(Date:6/24/2016)... ... , ... People across the U.S. are sharpening their pencils and honing their ... in which patients and their families pay tribute to a genetic counselor by nominating ... of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, ...
(Date:6/24/2016)... Las Vegas, Nevada (PRWEB) , ... June 24, ... ... their Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and ... The Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer ...
(Date:6/24/2016)... ... 24, 2016 , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. ... service members that have been wounded in battle and their families. Venture Construction Group ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at www.diabetesscholars.org by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (United States, China, Japan, Brazil, United Kingdom, Germany, France, ... Surgical Procedure Volumes: ... provides surgical procedure volume data in a geographic context. ... analysis of growth drivers and inhibitors, including world population ...
Breaking Medicine Technology: